Cepheid, Instrumentation Laboratories to Develop Hemostasis Dxs; IL to Market Them | GenomeWeb
NEW YORK (GenomeWeb News) — Cepheid and Instrumentation Laboratory intend to develop and distribute diagnostics for hemostasis applications, Cepheid said today.  
Under the agreement, Cepheid will develop tests to be used on its GeneXpert technology, while IL will market them as part of its panel of hemostasis diagnostic assays.
Cepheid said it first plans to develop the Xpert HemosIL tests to detect Factor II and Factor V mutations, which are genetic variations associated with thrombosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.